MRI Neurofeedback and Brain Circuits Related to Motivation in Healthy Participants
NCT05929898
Recruiting
The purpose of this research study is to understand how healthy individuals self-regulate motivation by observing brain activity using magnetic resonance imaging (MRI).
Gender:
ALL
Ages:
Between 18 years and 45 years
Trial Updated:
05/20/2025
Locations: Center for Cognitive Neuroscience, Durham, North Carolina
Conditions: Motivation, Memory, Self-regulation
Register for Updates
Hyperbaric Oxygen Therapy for Optic Neuropathies
NCT06128720
Recruiting
The purpose of the study is to evaluate the neuroprotective efficacy of hyperbaric oxygen for the treatment in patients with optic neuropathy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/20/2025
Locations: Byers Eye Institute, Palo Alto, California
Conditions: Optic Neuropathy, Glaucoma
Register for Updates
Novel Approaches for Improving Vascular Function in Veterans With HFpEF
NCT06312748
Recruiting
This project will evaluate the impact of L-Citrulline, tetrahydrobiopterin (BH4), and atorvastatin administration on physical capacity and vascular function in Veterans with heart failure with preserved ejection fraction (HFpEF).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/20/2025
Locations: VA Salt Lake City Health Care System, Salt Lake City, UT, Salt Lake City, Utah
Conditions: Inflammation, Heart Failure With Preserved Ejection Fraction
Register for Updates
Functional Neuroimaging to Detect the Neural Signatures of the Unpleasantness of Pain and Effort
NCT06472622
Recruiting
Background: The way the brain processes rewards and punishments may play a role in some disorders of the nervous system. People with chronic overlapping pain conditions (such as myalgic encephalomyelitis/chronic fatigue syndrome \[ME/CFS\]) may have heightened responses to unpleasant, punishing sensations. Some of these conditions may also cause heightened responses to effort; this is an unpleasant sensation felt during physical and mental exertion. Objective: To learn more about how the brai... Read More
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
05/20/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Fatigue Syndrome, Chronic
Register for Updates
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
NCT06676319
Recruiting
This is a parallel-group, Phase 2, randomized, double-blind, placebo-controlled, 2-arm study for the treatment of asthma. The purpose of this study is to assess the efficacy, safety, and tolerability of add-on therapy with SC lunsekimig compared with placebo in male and female participants (aged 18 to 80 years, inclusive) with asthma, who are not currently eligible for biologic treatments. Study details include: * The study duration will be approximately 64 weeks for participants not transiti... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
05/20/2025
Locations: Chandler Clinical Research Trials- Site Number : 8400075, Chandler, Arizona +159 locations
Conditions: Asthma
Register for Updates
Comparing The Safety And Efficacy Of DEFENCATH® In Reducing Central-Line Bloodstream Infections (CLABSIs) In Adults Receiving Total Parenteral Nutrition Through A Central Venous Catheter (CVC)
NCT06822426
Recruiting
This is a Phase 3, randomized, double-blind, controlled, adaptive, 2-arm, multicenter study to demonstrate the efficacy and safety of DefenCath in adult participants receiving home Total Parenteral Nutrition (TPN) via Central Venous Catheter (CVC) compared with heparin.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/20/2025
Locations: University of Iowa Health Care, Iowa City, Iowa
Conditions: Central Line Associated Blood Stream Infections (CLABSI)
Register for Updates
Decisions During Drinking
NCT06978140
Recruiting
Decisions during drinking (D3) is randomized clinical feasibility trial assessing whether health-related materials created for young adults who want to have more positive experiences if they decide to drink alcohol are acceptable and usable. Enrolled participants will be randomized to receive the health-related messages in 5-7 online modules over the 20-30 days or to only receive assessments. Those randomized to receive the intervention will also receive text-messages with health message content... Read More
Gender:
ALL
Ages:
Between 18 years and 24 years
Trial Updated:
05/20/2025
Locations: Center for the Study of Health and Risk Behavior, University of Washington, Seattle, Washington
Conditions: Alcohol
Register for Updates
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
NCT03629171
Recruiting
This phase II trial studies how well liposome-encapsulated daunorubicin-cytarabine and venetoclax work in treating participants with acute myeloid leukemia that has come back (relapsed), does not respond to treatment (refractory), or has not been treated (untreated). Drugs used in chemotherapy, such as liposome-encapsulated daunorubicin-cytarabine and venetoclax, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/20/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Register for Updates
A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD22 for Relapsed/Refractory Leukemia or Lymphoma
NCT04571138
Recruiting
Patients with relapsed or refractory leukemia or lymphoma are often refractory to further chemotherapy. In this study, the investigators will attempt to use T cells obtained directly from the patient, which can be genetically engineered to express a chimeric antigen receptor (CAR). The CAR used in this study can recognize CD22, a protein expressed on the surface of leukemia and lymphoma cells. The phase 1 part of this study will determine the safety and appropriate dose level of these CAR T cell... Read More
Gender:
ALL
Ages:
30 years and below
Trial Updated:
05/20/2025
Locations: Children's Hospital Los Angeles, Los Angeles, California +4 locations
Conditions: Leukemia, Lymphoma
Register for Updates
Loncastuximab Tesirine in WM
NCT05190705
Recruiting
This study is being done to examine the safety and effectiveness of loncastuximab tesirine as a possible treatment for participants with Waldenström Macroglobulinemia (WM). The name of the study drug involved in this study is: * Loncastuximab tesirine
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/20/2025
Locations: Dana Farber Cancer Institute, Boston, Massachusetts +3 locations
Conditions: Waldenstrom Macroglobulinemia
Register for Updates
Phase II Study of Peptide Receptor Radionuclide Therapy in Combination With Immunotherapy for Patients With Merkel Cell Cancer
NCT05583708
Recruiting
The purpose of this study is to find out what effects an immunotherapy drug, called pembrolizumab, combined with a radioactive drug, called lutetium Lu 177 dotatate (Lutathera®) have on patients with Merkel cell carcinoma. Pembrolizumab works by helping patient's immune system to fight cancer. Lutathera works by killing cancer cells. Pembrolizumab is approved by the FDA to treat Merkel cell cancer and has caused some Merkel cell cancers to shrink and/or resolve. Lutathera is FDA-approved to trea... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/20/2025
Locations: University of Iowa Hospitals and Clinics, Iowa City, Iowa +2 locations
Conditions: Merkel Cell Carcinoma
Register for Updates
Bacteriophage Therapy TP-102 in Patients With Diabetic Foot Infection
NCT05948592
Recruiting
TP-102 is a novel bacteriophage cocktail comprised of 5 (five) lytic bacteriophages against Staphylococcus aureus, Pseudomonas aeruginosa, and Acinetobacter baumannii. TP-102 is being developed for topical treatment of patients with wound infections including chronic ulcers; applied every other day (three times weekly (TIW)).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/20/2025
Locations: Clemente Clinical Research, Los Angeles, California +9 locations
Conditions: Diabetic Foot Infection
Register for Updates